Mauro A.M Carai
Research Subjects
Mauro A.M Carai has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
C Lobina
4 shared publications- Gian Luigi Gessa
B.B. Brodie' Department of Neuroscience, University of Cagliari, via Porcell, 4, 09124 Cagliari, Italy
4 shared publications G Colombo
3 shared publicationsGian Luigi Gessa
2 shared publicationsGiancarlo Colombo
University of Cagliari
2 shared publicationsGiorgio Cignarella
University of Milan
2 shared publications
Latest Publications
- Open Access
- 17 August 2011
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 46 (Supplement) , i28-i29
FREE ORAL COMMUNICATIONS 3: ALCOHOL-BRAIN: FROM BASIC TO CLINICAL RESEARCH * O3.1 * COMPARISON OF THE EFFECT OF THE GABA(B) RECEPTOR AGONIST, BACLOFEN, ON ALCOHOL SELF-ADMINISTRATION IN THREE DIFFERENT LINES OF ALCOHOL-PREFERRING RATS
Treatment with the GABA(B) receptor agonist, baclofen (BAC), has been reported to suppress multiple alcohol-related behaviors in rats and mice. The present study compared the effect of BAC on alcohol self-administration (S-A) in three lines of selectively bred, alcohol-preferring rats: Indiana (P), Sardinian (sP) and Alko Alcohol (AA) alcohol-preferring rats. To this end, rats of each line were trained to lever-respond on a Fixed Ratio 4 (FR4) to orally self-administer alcohol (15%, v/v) in daily 30-min sessions. Once responding stabilized, rats were exposed to a sequence of experiments testing BAC (0, 1, 1.7 and 3 mg/kg; i.p.) on FR4 and progressive ratio (PR) schedules of reinforcement. Specificity was assessed testing BAC on food-mantained responding. The rank of order of alcohol-reinforcing properties was: P > sP > AA rats. BAC was more potent and effective in suppressing alcohol S-A in P than sP and AA rats. Reduction in number of lever-responses, amount of self-administered alcohol and breakpoint for alcohol in P rats treated with 1.7 and 3 mg/kg BAC averaged approximately 50 and 80%, respectively. BAC-treated sP rats displayed intermediate values between those of P and AA rats. Only 3 mg/kg BAC reduced responding for food; this effect was common to all three rat lines. These results suggest that: (a) the strength of alcohol reinforcing properties differs among P, sP and AA rats; (b) alcohol-reinforcing properties in P, sP and AA rats are differentially sensitive to BAC; (c) the heterogeneity in sensitivity to BAC in P, sP and AA rats may resemble the differential sensitivity to pharmacotherapies among typologies of human alcoholics; (d) the GABA(B) receptor is likely part of the neural substrate mediating alcohol-reinforcing properties [see also the companion paper on GS39783 (Maccioni et al., this meeting)]. (This study was supported by Compagnia di San Paolo, Turin, Italy. P.M. is awardee of a fellowship from Regione Autonoma della Sardegna, PO Sardegna FSE 2007-2013, L.R. 7/2007.)
- 17 August 2011
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 46 (Supplement) , i28-i29
Open AccessFREE ORAL COMMUNICATIONS 3: ALCOHOL-BRAIN: FROM BASIC TO CLINICAL RESEARCH * O3.1 * COMPARISON OF THE EFFECT OF THE GABA(B) RECEPTOR AGONIST, BACLOFEN, ON ALCOHOL SELF-ADMINISTRATION IN THREE DIFFERENT LINES OF ALCOHOL-PREFERRING RATS
Treatment with the GABA(B) receptor agonist, baclofen (BAC), has been reported to suppress multiple alcohol-related behaviors in rats and mice. The present study compared the effect of BAC on alcohol self-administration (S-A) in three lines of selectively bred, alcohol-preferring rats: Indiana (P), Sardinian (sP) and Alko Alcohol (AA) alcohol-preferring rats. To this end, rats of each line were trained to lever-respond on a Fixed Ratio 4 (FR4) to orally self-administer alcohol (15%, v/v) in daily 30-min sessions. Once responding stabilized, rats were exposed to a sequence of experiments testing BAC (0, 1, 1.7 and 3 mg/kg; i.p.) on FR4 and progressive ratio (PR) schedules of reinforcement. Specificity was assessed testing BAC on food-mantained responding. The rank of order of alcohol-reinforcing properties was: P > sP > AA rats. BAC was more potent and effective in suppressing alcohol S-A in P than sP and AA rats. Reduction in number of lever-responses, amount of self-administered alcohol and breakpoint for alcohol in P rats treated with 1.7 and 3 mg/kg BAC averaged approximately 50 and 80%, respectively. BAC-treated sP rats displayed intermediate values between those of P and AA rats. Only 3 mg/kg BAC reduced responding for food; this effect was common to all three rat lines. These results suggest that: (a) the strength of alcohol reinforcing properties differs among P, sP and AA rats; (b) alcohol-reinforcing properties in P, sP and AA rats are differentially sensitive to BAC; (c) the heterogeneity in sensitivity to BAC in P, sP and AA rats may resemble the differential sensitivity to pharmacotherapies among typologies of human alcoholics; (d) the GABA(B) receptor is likely part of the neural substrate mediating alcohol-reinforcing properties [see also the companion paper on GS39783 (Maccioni et al., this meeting)]. (This study was supported by Compagnia di San Paolo, Turin, Italy. P.M. is awardee of a fellowship from Regione Autonoma della Sardegna, PO Sardegna FSE 2007-2013, L.R. 7/2007.)
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 78A
THE ROLE OF CANNABINOID RECEPTORS IN THE CONTROL OF ALCOHOL INTAKE.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 78A
THE ROLE OF CANNABINOID RECEPTORS IN THE CONTROL OF ALCOHOL INTAKE.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 74A
INVOLVEMENT OF CANNABINOID CB1 AND GABAB RECEPTORS IN THE CONTROL OF RELAPSE-LIKE DRINKING IN ALCOHOL-PREFERRING SP RATS.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 74A
INVOLVEMENT OF CANNABINOID CB1 AND GABAB RECEPTORS IN THE CONTROL OF RELAPSE-LIKE DRINKING IN ALCOHOL-PREFERRING SP RATS.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 18A
SACCHARIN AVAILABILITY PREVENTS THE ACQUISITION OF ALCOHOL DRINKING BEHAVIOR IN ALCOHOL-PREFERRING sP RATS.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 18A
SACCHARIN AVAILABILITY PREVENTS THE ACQUISITION OF ALCOHOL DRINKING BEHAVIOR IN ALCOHOL-PREFERRING sP RATS.
- 1 April 2002
- Published by Elsevier in European Journal of Pharmacology
- Vol. 441 (3) , 157-163
Central effects of 1,4-butanediol are mediated by GABAB receptors via its conversion into γ-hydroxybutyric acid
- 1 April 2002
- Published by Elsevier in European Journal of Pharmacology
- Vol. 441 (3) , 157-163
Central effects of 1,4-butanediol are mediated by GABAB receptors via its conversion into γ-hydroxybutyric acid
- 1 October 2001
- Published by Elsevier in European Journal of Pharmacology
- Vol. 428 (3) , 315-321
Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid
- 1 October 2001
- Published by Elsevier in European Journal of Pharmacology
- Vol. 428 (3) , 315-321
Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid
- 1 January 2000
- Vol. 24 (1) , 58-66
Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.
The similarities between the pharmacological effects of the gamma-aminobutyric acid receptor agonist, baclofen, and the alcohol-substituting agent, gamma-hydroxybutyric acid, led us to investigate whether baclofen was capable of reducing (a) ethanol withdrawal syndrome in ethanol-dependent rats and (b) voluntary ethanol intake in ethanol-preferring rats. In experiment 1, Wistar rats were rendered physically dependent on ethanol by the repeated administration of intoxicating doses of ethanol for 6 consecutive days. Baclofen was acutely administered intraperitoneally at doses of 10, 20, and 40 mg/kg. In experiment 2, baclofen (0, 2.5, 5, and 10 mg/kg, intraperitoneally) was administered once a day for 14 consecutive days to ethanol-preferring sP rats that had continuous access to ethanol (10%, v/v) and water under the two-bottle free choice regimen. In experiment 1, baclofen dose-dependently decreased the intensity of ethanol withdrawal signs; furthermore, 20 mg/kg of baclofen protected from audiogenic seizures in ethanol-withdrawn rats. In experiment 2, baclofen selectively and dose-dependently reduced voluntary ethanol intake; a compensatory increase in water intake left total fluid intake virtually unchanged. These results are in close agreement with those of a preliminary clinical study and suggest that baclofen may constitute a novel therapeutic agent for alcoholism.
- 1 January 2000
- Vol. 24 (1) , 58-66
Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.
The similarities between the pharmacological effects of the gamma-aminobutyric acid receptor agonist, baclofen, and the alcohol-substituting agent, gamma-hydroxybutyric acid, led us to investigate whether baclofen was capable of reducing (a) ethanol withdrawal syndrome in ethanol-dependent rats and (b) voluntary ethanol intake in ethanol-preferring rats. In experiment 1, Wistar rats were rendered physically dependent on ethanol by the repeated administration of intoxicating doses of ethanol for 6 consecutive days. Baclofen was acutely administered intraperitoneally at doses of 10, 20, and 40 mg/kg. In experiment 2, baclofen (0, 2.5, 5, and 10 mg/kg, intraperitoneally) was administered once a day for 14 consecutive days to ethanol-preferring sP rats that had continuous access to ethanol (10%, v/v) and water under the two-bottle free choice regimen. In experiment 1, baclofen dose-dependently decreased the intensity of ethanol withdrawal signs; furthermore, 20 mg/kg of baclofen protected from audiogenic seizures in ethanol-withdrawn rats. In experiment 2, baclofen selectively and dose-dependently reduced voluntary ethanol intake; a compensatory increase in water intake left total fluid intake virtually unchanged. These results are in close agreement with those of a preliminary clinical study and suggest that baclofen may constitute a novel therapeutic agent for alcoholism.